Genomic DNA at the intended Coagulation Factor IX (F9) insertion locus in hepatocytes (F9 insertion locus)

Genomic DNA at the intended Coagulation Factor IX (F9) insertion locus in hepatocytes refers to the specific chromosomal site targeted for the therapeutic integration of a functional F9 transgene. In the context of Hemophilia B treatment, this target is frequently the Albumin (ALB) locus due to its high transcriptional activity in liver cells, which allows for the robust production of the Factor IX protein (Sangamo Therapeutics, 2019). The biological objective is to leverage the liver's protein synthesis machinery to secrete Factor IX into the systemic circulation, thereby restoring normal blood clotting function (PubMed: 31034577). Therapeutic agents such as Zinc Finger Nucleases (ZFNs), specifically SB-FIX, are designed to recognize and cleave this specific DNA sequence to facilitate the insertion of the F9 gene via homology-independent targeted integration (Nature Communications, 2019). This target is central to "in vivo" genome editing strategies that aim to provide a durable, one-time treatment for patients with Factor IX deficiency (NIH, 2021). Successful modification of this locus results in the long-term secretion of functional Factor IX, potentially eliminating the need for regular factor replacement therapy. Monitoring this target involves assessing genomic integration efficiency and potential off-target effects that could lead to oncogenesis or other cellular dysfunctions (StatPearls, 2023). Safety concerns include the risk of insertional mutagenesis and the potential for an immune response against the viral vectors used for delivery. This approach represents a significant advancement in precision medicine for monogenic disorders. The specificity of the nuclease for this locus is critical for minimizing unintended genomic alterations.

Other names

Albumin locus (ALB) for F9 insertionFactor IX gene insertion siteHepatocyte F9 genomic targetF9 safe harbor locus

Site-specific genomic integration of a functional F9 transgene via engineered nucleases (e.g., ZFNs) to restore Factor IX production in the liver.